{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:00:31Z","timestamp":1794963631525,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.pcad.2019.07.003","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T19:57:07Z","timestamp":1564689427000},"page":"298-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":221,"title":["Diabetes, heart failure, and renal dysfunction: The vicious circles"],"prefix":"10.1016","volume":"62","author":[{"given":"Eugene","family":"Braunwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2019.07.003_bb0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40256-019-00325-9","article-title":"Cardiovascular protection with anti-hyperglycemic agents","volume":"19","author":"Deedwania","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pcad.2019.07.003_bb0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2019.07.003_bb0015","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2337\/dc17-1962","article-title":"Global economic burden of diabetes in adults: projections from 2015 to 2030","volume":"41","author":"Bommer","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2019.07.003_bb0020","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2019.07.003_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.pcad.2019.07.003_bb0030","series-title":"Atlanta, GA: U.S","first-page":"2019","author":"Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States","year":"2019"},{"key":"10.1016\/j.pcad.2019.07.003_bb0035","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2019.07.003_bb0040","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/aje\/kwf111","article-title":"Age and the burden of death attributable to diabetes in the United States","volume":"156","author":"Saydah","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.pcad.2019.07.003_bb0045","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2337\/dc17-2583","article-title":"Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction","volume":"41","author":"Rorth","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2019.07.003_bb0050","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovic","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2019.07.003_bb0055","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics \u2013 2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2019.07.003_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2016.07.025","article-title":"Temporal trends and factors associated with diabetes mellitus among patient hospitalized with heart failure: findings from get with the guidelines \u2013 heart failure registry","volume":"182","author":"Echouffo-Tcheugui","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2019.07.003_bb0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0002-9343(03)00072-X","article-title":"Higher incidence of new-onset diabetes in patients with heart failure","volume":"114","author":"Grundy","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2019.07.003_bb0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0002-9343(02)01530-9","article-title":"Functional class in patients with heart failure is associated with the development of diabetes","volume":"114","author":"Tenenbaum","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2019.07.003_bb0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/eurjhf\/hfq204","article-title":"Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices","volume":"13","author":"Uriel","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2019.07.003_bb0080","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2019.07.003_bb0085","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1093\/eurheartj\/ehy596","article-title":"Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association \u2013 European Society of Cardiology","volume":"39","author":"Maack","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2019.07.003_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/eurjhf\/hfs156","article-title":"Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta analysis","volume":"15","author":"Ergou","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2019.07.003_bb0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (ukpds 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2019.07.003_bb0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye and Vision"},{"key":"10.1016\/j.pcad.2019.07.003_bb0105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/dc17-0755","article-title":"The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction","volume":"41","author":"Sandesara","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2019.07.003_bb0110","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.jacc.2019.03.002","article-title":"Influence of microvascular disease on cardiovascular events in type 2 diabetes","volume":"73","author":"Verma","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2019.07.003_bb0115","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cmet.2012.04.006","article-title":"Lipid metabolism and toxicity in the heart","volume":"15","author":"Goldberg","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.pcad.2019.07.003_bb0120","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.pcad.2019.07.003_bb0125","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/cvr\/cvx011","article-title":"An overview of the inflammatory signaling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy","volume":"113","author":"Frati","year":"2017","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pcad.2019.07.003_bb0130","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2019.07.003_bb0135","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1161\/01.CIR.102.18.2180","article-title":"Coronary composition and macrophage infiltration in atherectomy specimens from patient with diabetes mellitus","volume":"102","author":"Moreno","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2019.07.003_bb0140","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.2337\/dc08-0282","article-title":"Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome","volume":"31","author":"Undas","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2019.07.003_bb0145","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1538-7836.2004.00836.x","article-title":"Platelet activation in type 2 diabetes mellitus","volume":"2","author":"Ferroni","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pcad.2019.07.003_bb0150","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1538-7836.2010.03910.x","article-title":"Hyperglycemia: a prothrombotic factor","volume":"8","author":"Lemkes","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pcad.2019.07.003_bb0155","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovic","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2019.07.003_bb0160","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/CIRCRESAHA.118.314665","article-title":"Diabetic cardiomyopathy: what is it and can it be fixed?","volume":"124","author":"Dillmann","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.pcad.2019.07.003_bb0165","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2019.07.003_bb0170","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pcad.2019.07.003_bb0175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.23876\/j.krcp.2018.37.2.106","article-title":"Pathology identifies glomerular treatment targets in diabetic nephropathy","volume":"37","author":"Alpers","year":"2018","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.pcad.2019.07.003_bb0180","doi-asserted-by":"crossref","DOI":"10.1159\/000499486","article-title":"Consequences of glomerular hyperfiltration: the role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity","author":"Chagnac","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.pcad.2019.07.003_bb0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcjd.2014.10.013","article-title":"Uric acid as a biomarker and a therapeutic target in diabetes","volume":"39","author":"Lytvyn","year":"2015","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.pcad.2019.07.003_bb0190","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2019.07.003_bb0195","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2019.07.003_bb0200","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2019.07.003_bb0205","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2019.07.003_bb0210","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2019.07.003_bb0215","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/dbi18-0007","article-title":"Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease","volume":"68","author":"Alcic","year":"2019","journal-title":"Diabetes"},{"issue":"suppl 1","key":"10.1016\/j.pcad.2019.07.003_bb0220","first-page":"S4","article-title":"Standards of medical Care in Diabetes \u2013 2019","volume":"42","author":"Summary of revisions","year":"2019","journal-title":"Diabetes Care"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062019301008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062019301008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:15:55Z","timestamp":1758500155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062019301008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0033062019301008"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2019.07.003","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes, heart failure, and renal dysfunction: The vicious circles","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2019.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}